Tacrolimus/vincristine

“ Author Information ”

“

An event is serious (based on the ICH definition) when the patient outcome is:

• * death

• * life-threatening

• * hospitalisation

• * disability

• * congenital anomaly

• * other medically important event

”

“ ”

In a study of 37 patients initiated by the French society of paediatric oncology (SFCE), two patients including an 18-year-old woman [not all ages and sexes stated] were described, who developed coronavirus disease-2019 (COVID-19) during chemotherapy with vincristine for B-acute lymphocytic leukaemia (B-ALL) or immunosuppression with tacrolimus in France.

The patients had been receiving chemotherapy vincristine for relapsed B-ALL (n=1) and immunosuppression with tacrolimus (n=1) [routes and dosages not stated]. The patients developed COVID-19 infection [durations of treatment to reactions onset not stated].

One woman (the 18-year-old) required intensive care unit admission and non-invasive ventilation. She received off-label treatment with hydroxychloroquine and had favourable prognosis. She was discharged after 10 days of admission. She was scheduled for chimeric antigen receptor T cells (CART) therapy, but was delayed due to severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) [not all outcomes stated].